ZIMBABWE is ready to transition to Teno-Lamuvudine Dolutegrevir (TLD), an Anti-retro Viral (ARV) drug with less side effects, moving away from the Teno-Lamivudine-Efavirenz (TLE) a three in one drug that is taken once a day, a top health official has said By Michael Gwarisa The development comes barely a year after government through the Ministry